DK1471871T3 - Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin - Google Patents

Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Info

Publication number
DK1471871T3
DK1471871T3 DK02724904T DK02724904T DK1471871T3 DK 1471871 T3 DK1471871 T3 DK 1471871T3 DK 02724904 T DK02724904 T DK 02724904T DK 02724904 T DK02724904 T DK 02724904T DK 1471871 T3 DK1471871 T3 DK 1471871T3
Authority
DK
Denmark
Prior art keywords
erythropoietin
treatment
neurological dysfunction
dysfunction including
fructopyranose sulfamates
Prior art date
Application number
DK02724904T
Other languages
Danish (da)
English (en)
Inventor
Salaman Carlos Plata
Virginia Smith-Swintosky
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1471871T3 publication Critical patent/DK1471871T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK02724904T 2001-02-02 2002-01-24 Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin DK1471871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26619401P 2001-02-02 2001-02-02
PCT/US2002/003096 WO2002064085A2 (en) 2001-02-02 2002-01-24 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Publications (1)

Publication Number Publication Date
DK1471871T3 true DK1471871T3 (da) 2007-09-17

Family

ID=23013568

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02724904T DK1471871T3 (da) 2001-02-02 2002-01-24 Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Country Status (17)

Country Link
US (2) US6908902B2 (de)
EP (1) EP1471871B1 (de)
JP (1) JP2005501801A (de)
KR (1) KR100896971B1 (de)
AT (1) ATE361089T1 (de)
CA (1) CA2437333A1 (de)
CY (1) CY1106733T1 (de)
DE (1) DE60219961T8 (de)
DK (1) DK1471871T3 (de)
ES (1) ES2284858T3 (de)
MX (1) MXPA03006952A (de)
NO (1) NO20033440L (de)
NZ (1) NZ548578A (de)
PT (1) PT1471871E (de)
RU (1) RU2317086C2 (de)
WO (1) WO2002064085A2 (de)
ZA (1) ZA200306818B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP1471871B1 (de) * 2001-02-02 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
CA2459146A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
EP1815854A1 (de) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Behandlung von Dyskinesie
WO2004026299A1 (en) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Treatment of dyskinesia
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de) * 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2007020922A1 (ja) * 2005-08-17 2007-02-22 Chugai Seiyaku Kabushiki Kaisha 脳疾患の治療剤および予防剤
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AU2008282496B2 (en) * 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
EA201001814A1 (ru) * 2008-05-22 2011-04-29 Эдисон Фармасьютикалз, Инк. Лечение митохондриальных заболеваний миметиками эритропоэтина
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
EP2485761B1 (de) * 2009-10-09 2019-02-27 Armagen, Inc. Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns
CA2857647C (en) 2011-12-02 2022-04-19 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
EP2829270B1 (de) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Verbindungsprodukt mit synephrin und topiramat
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
EP0710102A1 (de) 1993-07-19 1996-05-08 Amgen Inc. Stabilisierung von proteinen in aerosolform
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
JP4410852B2 (ja) 1996-08-02 2010-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 単一の共有結合ｎ末端水溶性ポリマーを有するポリペプチド
EP0986644B1 (de) 1997-07-23 2006-10-04 Boehringer Mannheim GmbH Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
PT902085E (pt) 1997-09-01 2004-02-27 Aventis Pharma Gmbh Eritropoietina humana recombinante com perfil de glicosilacao vantajoso
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
ES2273497T3 (es) 1998-06-15 2007-05-01 Gtc Biotherapeutics, Inc. Proteina de fusion de la albumina serica humana de eritropoyetina analoga.
WO2000061138A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
EP1471871B1 (de) * 2001-02-02 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin

Also Published As

Publication number Publication date
ATE361089T1 (de) 2007-05-15
ES2284858T3 (es) 2007-11-16
NO20033440L (no) 2003-09-29
CA2437333A1 (en) 2002-08-22
RU2317086C2 (ru) 2008-02-20
WO2002064085A2 (en) 2002-08-22
EP1471871A4 (de) 2005-11-09
RU2003124059A (ru) 2005-01-27
DE60219961T8 (de) 2008-04-17
US20020169109A1 (en) 2002-11-14
CY1106733T1 (el) 2012-05-23
KR20040011458A (ko) 2004-02-05
PT1471871E (pt) 2007-06-05
DE60219961D1 (de) 2007-06-14
WO2002064085A3 (en) 2004-09-10
ZA200306818B (en) 2005-02-23
US6908902B2 (en) 2005-06-21
EP1471871B1 (de) 2007-05-02
JP2005501801A (ja) 2005-01-20
DE60219961T2 (de) 2008-01-17
KR100896971B1 (ko) 2009-05-14
US20050261182A1 (en) 2005-11-24
NZ548578A (en) 2008-03-28
MXPA03006952A (es) 2004-10-15
EP1471871A2 (de) 2004-11-03
NO20033440D0 (no) 2003-08-01

Similar Documents

Publication Publication Date Title
DK1471871T3 (da) Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
MX231981B (es) Tratamiento de semillas con combinaciones de piretrinas/piretroides y clotianidina.
MX237325B (es) Tratamiento para semilla con combinaciones de insecticidas
IS6806A (is) Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
NO20011964D0 (no) Brönnbehandlingsfluider og fremgangsmåter med anvendelse derav
MX238203B (es) Tratamiento de semillas con combinaciones de piretrinas, piretroides y tlametoxam.
DK1392292T3 (da) Pyranoindazoler og deres anvendelse til behandling af glaukom
ITBO20000453A0 (it) Apparecchiatura e procedimento per la sterilizzazione del terreno .
MY135829A (en) Analeptic and drug combinations
DK1383742T3 (da) Syntese og fremgangsmåder til anvendelse af tetrahydroindolonanaloge og derivater
AU2001222215A1 (en) Lumbago treating girdle
DE60200302D1 (de) Laseraugenbehandlungseinrichtung
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
NO20023944D0 (no) Blanding og metoder for behandling av epilepsi
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
ATE333439T1 (de) Pflanzenkläranlage
BR0103928B1 (pt) equipamento para tratamento de efluentes e estação para tratamento de efluentes.
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
FR2825913B1 (fr) Stimulateur central hydro-dynamogene des membres inferieurs
NO20014850L (no) CML-terapi
FI5249U1 (fi) Kantojenkäsittelylaitteisto
FI5282U1 (fi) Jäteveden puhdistamo